PMID- 18438105
OWN - NLM
STAT- MEDLINE
DCOM- 20080807
LR  - 20190516
IS  - 1554-8619 (Electronic)
IS  - 1554-8600 (Linking)
VI  - 4
IP  - 1
DP  - 2008 Jan-Feb
TI  - A comparison of anionic nanoparticles and microparticles as vaccine delivery 
      systems.
PG  - 44-9
AB  - The objective of this work was to conduct an in vivo comparison of nanoparticles 
      and microparticles as vaccine delivery systems. Poly (lactide-co-glycolide) (PLG) 
      polymers were used to create nanoparticles size 110 nm and microparticles of size 
      800-900 nm. Protein antigens were then adsorbed to these particles. The efficacy 
      of these delivery systems was tested with two protein antigens. A recombinant 
      antigen from Neisseria meningitides type B (MenB) was administered 
      intramuscularly (i.m.) or intraperitonealy (i.p.). An antigen from HIV-1, env 
      glycoprotein gp140 was administered intranasally (i.n.) followed by an i.m. 
      boost. From three studies, there were no differences between the nanoparticles 
      and micro-particles formulations. Both particles led to comparable immune 
      responses in mice. The immune responses for MenB (serum bactericidal activity and 
      antibody titers) were equivalent to the control of aluminum hydroxide. For the 
      gp140, the LTK63 was necessary for high titers. Both nanoparticles and 
      microparticles are promising delivery systems.
FAU - Wendorf, Janet
AU  - Wendorf J
AD  - Novartis Vaccines and Diagnostics, Inc., Emeryville, CA 94608, USA.
FAU - Chesko, James
AU  - Chesko J
FAU - Kazzaz, Jina
AU  - Kazzaz J
FAU - Ugozzoli, Mildred
AU  - Ugozzoli M
FAU - Vajdy, Michael
AU  - Vajdy M
FAU - O'Hagan, Derek
AU  - O'Hagan D
FAU - Singh, Manmohan
AU  - Singh M
LA  - eng
PT  - Journal Article
DEP - 20070815
PL  - United States
TA  - Hum Vaccin
JT  - Human vaccines
JID - 101265291
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Anions)
RN  - 0 (Antigens, Bacterial)
RN  - 0 (env Gene Products, Human Immunodeficiency Virus)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
SB  - IM
MH  - Adjuvants, Immunologic/chemistry
MH  - Animals
MH  - Anions/administration & dosage
MH  - Antigens, Bacterial/administration & dosage/metabolism
MH  - Chemistry, Pharmaceutical
MH  - *Drug Delivery Systems
MH  - Lactic Acid/administration & dosage/*chemistry
MH  - Mice
MH  - Microspheres
MH  - Nanoparticles/*administration & dosage
MH  - Neisseria meningitidis, Serogroup B/chemistry/immunology
MH  - Polyglycolic Acid/administration & dosage/*chemistry
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - env Gene Products, Human Immunodeficiency Virus/*administration & 
      dosage/chemistry/immunology
EDAT- 2008/04/29 09:00
MHDA- 2008/08/08 09:00
CRDT- 2008/04/29 09:00
PHST- 2008/04/29 09:00 [pubmed]
PHST- 2008/08/08 09:00 [medline]
PHST- 2008/04/29 09:00 [entrez]
AID - 4886 [pii]
AID - 10.4161/hv.4.1.4886 [doi]
PST - ppublish
SO  - Hum Vaccin. 2008 Jan-Feb;4(1):44-9. doi: 10.4161/hv.4.1.4886. Epub 2007 Aug 15.